Healthcare · NSE/BSE: PPLPHARMA
Piramal Pharma Limited
Pharmaceuticals
Market Cap ₹0.22L Cr
Verdict: Average
Quality Scores
Multi-Bagger
48/100
Compounder Quality
52/100
Management Credibility
65/100
Governance
85/100
Cash Flow Quality
78/100
AI Summary
Piramal Pharma Limited (PPL) is an integrated pharmaceutical player specializing in CDMO, Complex Hospital Generics, and Consumer Healthcare. Since its demerger from Piramal Enterprises, the company has struggled with operational volatility and margin contraction, though revenue has grown at a modest 7% CAGR over 5 years. The business model is high-quality, serving regulated markets like the US and Europe, but the financials reflect a period of heavy reinvestment and debt-fueled growth. Asset turns remain low as the company digests significant CAPEX into its CDMO and manufacturing sites.…
Top Opportunities
- Top 3 CDMO player in India
- 13th largest CDMO globally
- High share (84%) from regulated markets (US/EU/Japan)
Top Risks
- Net Loss reported in FY23 and FY26
- Significant operating margin compression over 5 years
- Extremely high inventory days (345 days in FY26)
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.